{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:40:45Z","timestamp":1788320445857,"version":"build-2803163510"},"reference-count":20,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Plasmablastic multiple myeloma (MM) is a rare and highly aggressive variant of MM that presents significant diagnostic and therapeutic challenges. This variant is characterised by a bone marrow infiltration of \u22652% plasmablasts and is distinguished by its atypical pleomorphic morphology, unique immunohistological profile and extensive extramedullary involvement. The anaplastic features of plasmablastic MM can closely mimic those of high-grade lymphomas, leukaemia, non-haematopoietic malignancies and high-grade carcinomas, often leading to initial diagnostic errors. Accurate diagnosis requires a thorough evaluation that integrates clinical history, radiological findings, morphological analysis, immunophenotyping and genetic markers. Here, we present the case of a woman in her early 70s who was diagnosed with high-risk plasmablastic MM. The patient, with no significant neoplastic history, presented with chronic pain and an acute fracture, initially raising suspicion for high-grade metastatic lung carcinoma.<\/jats:p>","DOI":"10.1136\/bcr-2024-263120","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:25:34Z","timestamp":1732677934000},"page":"e263120","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Plasmablastic multiple myeloma presenting as a pleural mass: a diagnostic challenge"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-1869","authenticated-orcid":false,"given":"Maciej","family":"Kabat","sequence":"first","affiliation":[{"name":"Internal Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanisha","family":"Patel","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritish","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Pathology, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2025082706513549000_17.11.e263120.1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"2025082706513549000_17.11.e263120.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"2025082706513549000_17.11.e263120.3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145078"},{"key":"2025082706513549000_17.11.e263120.4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s00277-018-3316-7","article-title":"Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients","volume":"97","author":"Gonz\u00e1lez-Calle","year":"2018","journal-title":"Ann Hematol"},{"key":"2025082706513549000_17.11.e263120.5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clml.2016.06.001","article-title":"Revised International Staging System Applied to Real World Multiple Myeloma Patients","volume":"16","author":"Jimenez-Zepeda","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082706513549000_17.11.e263120.6","unstructured":"mSMART . mSMART. n.d. Available: https:\/\/www.msmart.org"},{"key":"2025082706513549000_17.11.e263120.7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.V65.2.305.305","article-title":"Multiple myeloma: significance of plasmablastic subtype in morphological classification","volume":"65","author":"Greipp","year":"1985","journal-title":"Blood"},{"key":"2025082706513549000_17.11.e263120.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02791.x"},{"key":"2025082706513549000_17.11.e263120.9","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/87.3.342"},{"key":"2025082706513549000_17.11.e263120.10","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic Morphology\u2014An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"key":"2025082706513549000_17.11.e263120.11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/apm.12411","article-title":"Clinicopathological features of plasmablastic multiple myeloma: a population\u2010based cohort","volume":"123","author":"M\u00f8ller","year":"2015","journal-title":"APMIS"},{"key":"2025082706513549000_17.11.e263120.12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36502\/2022\/ASJBCCR.6255","article-title":"Anaplastic Multiple Myeloma: Case Series and Literature Review","volume":"5","author":"Wu","year":"2022","journal-title":"Asploro J Biomed Clin Case Rep"},{"key":"2025082706513549000_17.11.e263120.13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701943"},{"key":"2025082706513549000_17.11.e263120.14","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPENJ68FFBRIYB"},{"key":"2025082706513549000_17.11.e263120.15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","article-title":"Plasma cell morphology in multiple myeloma and related disorders","volume":"99","author":"Ribourtout","year":"2015","journal-title":"Morphologie"},{"key":"2025082706513549000_17.11.e263120.16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800355"},{"key":"2025082706513549000_17.11.e263120.17","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204294"},{"key":"2025082706513549000_17.11.e263120.18","unstructured":"Plasmablastic myeloma: differentiating a high risk disease. 2022 Available: https:\/\/imagebank.hematology.org\/image\/63924\/plasmablastic-myeloma-differentiating-a-high-risk-disease"},{"key":"2025082706513549000_17.11.e263120.19","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.516040"},{"key":"2025082706513549000_17.11.e263120.20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0297"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:51:44Z","timestamp":1756302704000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,26]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bcr-2024-263120"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263120","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}